Mutation patterns in seven genes may help predict outcomes for individuals with follicular lymphoma
A study by the BC Cancer Agency in collaboration with scientists at the University Hospital of the Ludwig-Maximilians, University Munich, and collaborators at the Dana Farber Cancer Institute in Boston, developed a test coined m7-FLIPI, which identifies follicular lymphoma patients at the highest risk for treatment failure.
Follicular lymphoma is a subtype of non-Hodgkin lymphoma and while effective treatments exist, approximately 20 per cent of patients respond poorly or not at all to current therapies.
m7-FLIPI is the first prognostic model in follicular lymphoma that accounts for clinical factors and genetic mutations. It is an effective tool that has the power to save and extend patients’ lives by steering clinicians toward more innovative and effective treatment options.